Jonathan Rigby is an accomplished executive with a proven track record in the pharmaceutical, biotech, and drug delivery industry across the United States, Europe, and Israel. Serving as CEO, President, Board Member, and Chairman. Having privately and publicly financed three bio / pharma companiesJonathan excels in leading strategic initiatives, building great teams that execute, problem-solving, and challenging processes to drive drug product innovation, shareholder value, and employee satisfaction.With extensive experience founding and leading three specialty pharma and biotech companies, Jonathan has earned a reputation for overcoming challenging obstacles and successfully advancing drug products from development through launch. His expertise spans strategic foresight, exemplary leadership, corporate growth, capital raising, including four IPO’s and two public to public company mergers. His track record of problem-solving, assumption challenging, outcome optimization, convincing communication, and positive culture building has led to extensive value creation.In his recent role as President, Board Member and Group CEO of Revolo Biotherapeutics, Jonathan led the transformative change of a pre-clinical company to a clinical-stage immunology-focused Biotech company in a time and cost-efficient fashion. Under his leadership, the company secured significant private financing, established a strong management team, and advanced drug products for autoimmune and inflammatory allergic diseases through four clinical trials, inc two Phase 2a trials with positive data.As Chairman and Chief Business Officer of BIOS acquisition company, Jonathan co-led a successful Nasdaq IPO and spearheaded the merger agreement with a U.S company focused on cardiology. Jonathan's entrepreneurial spirit is evident in his founding and growth of SteadyMed Therapeutics, Inc., where he developed a drug product to treat Pulmonary Hypertension, raised substantial capital from investors such as Deerfield, Federated and Orbimed leading to an IPO. After leading a successful IP challenge Jonathan orchestrated a public-to-public company acquisition of SteadyMed by United Therapeutics (Nasdaq: UTHR).Prior to SteadyMed Jonathan co-founded Zogenix Inc with tier 1 investors, played a key role in its Nasdaq IPO. Zogenix was acquired by UCB in a multibillion-dollar transaction.